Table 4.

Association between ABCB1 2677G>T/A genotypes and progression-free survival in the validation data set from the SCOTROC1

ABCB1 genotypeCases, n (%)Relapse, n (%)Progression-free survival, HR (95% CI), P value
UnadjustedAdjusted*
Optimally debulked (residual disease ≤2 cm) treated with paclitaxel and carboplatin
    GG67 (24.1)34 (23.6)1.001.00
    GA/GT + TT/TA211 (75.9)110 (76.4)1.07 (0.72-1.57), P = 0.6250.99 (0.68-1.57), P = 0.485
  • * Adjusted for FIGO stage and residual disease.

  • One-sided hypothesis test for better progression-free survival among T/A allele carriers compared with GG homozygotes.